Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

Cancer patients with wasting syndrome have gained weight after taking Pfizer’s anti-GDF-15 antibody in a midphase study, ...

Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation ...

Pfizer Inc. (NYSE: PFE) experienced a notable uptick in its stock price during Monday’s trading session, climbing by +2.12% to reach $29.89 at 11:10 AM EDT. This positive movement comes in the wake of ...

The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...

Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results ...

Pfizer’s experimental cancer weight loss drug helped patients regain weight in a mid-stage study giving fresh promise for the ...

Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial.

Treatment related adverse events occurred in 8.9% of patients taking placebo and 7.7% of patients taking ponsegromab.i Based on these positive results, Pfizer is discussing late-stage development ...